Evommune

Explore the latest insights on Evommune and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Evommune’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Hybio Pharmaceutical's HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market
CompanyDrug

Hybio Pharmaceutical’s HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that its investigational drug HY3003 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), clearing the way…

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now